


1632.



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on March 25, 2003.

INFORMATION DISCLOSURE
STATEMENT
Examining Group 1632
Patent Application
Docket No. UF-216C1
Serial No. 10/062,623

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

RECEIVED
APR 02 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Not yet assigned)
Art Unit : 1632
Applicants : Dov Borovsky, Arnold De Loof, Peter Verhaert
Serial No. : 10/062,623
Filed : January 31, 2002
For : Neuropeptides and Their Use for Pest Control

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,
Glenn P. Ladwig
Glenn P. Ladwig
Patent Attorney
Registration No. 46,853
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

GPL/mv
Attachments: Form PTO/SB/08 (8 pages); copies of references cited therein



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → ☐ +
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+ RECEIVED

TECH CENTER 1600 2000
APR 01 2003

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 8			Complete if Known	
			Application Number	10/062,623
			Filing Date	January 31, 2002
			First Named Inventor	Dov Borovsky
			Group Art Unit	1632
			Examiner Name	
			Attorney Docket Number	UF-216C1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	U1	6,413,530		Borovsky et al.	07-02-2002	All
	U2	5,849,525		Hediger	12-15-1998	All
	U3	5,792,750		Borovsky et al.	08-11-1998	All
	U4	5,753,615		Thorpe et al.	05-19-1998	All
	U5	5,629,196		Borovsky et al.	05-13-1997	All
	U6	5,459,130		Borovsky et al.	10-17-1995	All
	U7	5,439,821		Borovsky et al.	08-08-1995	All
	U8	5,428,147		Barker et al.	06-27-1995	All
	U9	5,358,934		Borovsky et al.	10-25-1994	All
	U10	4,714,763		Theodoropoulos	12-22-1987	All
	U11	09/551,738		Borovsky (patent application)	04-18-2000	All
	U12	09/551,737		Borovsky et al. (patent application)	04-18-2000	All
	U13	09/296,113		Borovsky (patent application)	04-21-1999	All
	U14	09/295,924		Bennett et al. (patent application)	04-21-1999	All
	U15	09/295,846		Borovsky (patent application)	04-21-1999	All
	U16					
	U17					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	F1	WO	98/21348	✓ A1	Battelle Memorial Inst.	05-22-1998	All	
	F2	WO	95/24423	✓ A1	Queen Mary Westfield Coll.	09-14-1995	All	
	F3	WO	94/13698	✓ A1	Univ. of Florida	06-23-1994	All	
	F4	EP	0 682 115	✓ A1	Mycogen Plant Sci, Inc.	11-15-1995	All	
	F5	EP	0412595	✓ A1	Merck & Co., Inc.	02-13-1991	All	
	F6	JP	07 188282	✓	Masuami, Y.	07-25-1995	All	
	F7	JP	01 226898	✓	Ajinomoto, KK	09-11-1989	All	
	F8							
	F9							
	F10							

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 8

Complete if Known

Application Number	10/062,623
Filing Date	January 31, 2002
First Named Inventor	Dov Borovsky
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	UF-216C1

TECH CENTER 1600/2003

+ RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	U1	5,800,811		Hall et al.	09-01-1998	All
	U2	5,656,260		Boden et al.	08-12-1997	All
	U3	5,273,749		Bok et al.	12-28-1993	All
	U4	5,508,264		Bradfish et al.	04-16-1996	All
	U5	5,141,744		Chang et al.	08-25-1992	All
	U6	5,749,168		Chrysanthis	05-12-1998	All
	U7	5,713,153		Cook et al.	02-03-1998	All
	U8	5,513,465		Demarest et al.	05-07-1996	All
	U9	5,612,047		Duffy et al.	03-18-1997	All
	U10	5,676,958		Emerson et al.	10-14-1997	All
	U11	5,250,515		Fuchs et al.	10-05-1993	All
	U12	4,266,074		Fujimoto et al.	05-05-1981	All
	U13	5,714,191		Hatton et al.	02-03-1998	All
	U14	5,604,121		Hilder et al.	02-18-1997	All
	U15	5,688,764		Johnson et al.	11-18-1997	All
	U16	5,344,821		Kingan et al.	09-06-1994	All
	U17	5,741,669		Krapcho et al.	04-21-1998	All

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	F1							
	F2							
	F3							
	F4							
	F5							
	F6							
	F7							
	F8							
	F9							
	F10							

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 3 of 8			Complete if Known	
			Application Number	10/062,623
			Filing Date	January 31, 2002
			First Named Inventor	Dov Borovsky
			Group Art Unit	1632
			Examiner Name	
			Attorney Docket Number	UF-216C1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	U1	5,693,344		Knight et al.	12-02-1997	All
	U2	4,985,251		Levy	01-15-1991	All
	U3	4,983,390		Levy	01-08-1991	All
	U4	5,824,328		Levy	10-20-1998	All
	U5	5,567,430		Levy	10-22-1996	All
	U6	5,846,553		Levy	12-08-1998	All
	U7	5,522,171		Mandeville	06-04-1996	All
	U8	5,683,687		Marin et al.	11-04-1997	All
	U9	5,093,362		Milner et al.	03-03-1992	All
	U10	5,840,293		Nacht et al.	11-24-1998	All
	U11	5,259,153		Olive et al.	11-09-1993	All
	U12	5,348,665		Shulte et al.	09-20-1994	All
	U13	5,737,870		Thind	04-14-1998	All
	U14	5,527,883		Thompson et al.	06-18-1996	All
	U15	5,676,846		Vickell et al.	10-14-1997	All
	U16	RE34,402		Williams	10-12-1993	All
	U17	5,670,145		Wright	09-23-1997	All
	U18	5,399,344		Yang et al.	03-21-1995	All

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	F1							
	F2							
	F3							
	F4							
	F5							
	F6							
	F7							
	F8							
	F9							
	F10							


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

8

Complete if Known

Application Number	10/062,623
Filing Date	January 31, 2002
First Named Inventor	Dov Borovsky
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	UF-216C1

APR 02 2003
RECEIVED

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ALLEFS, S. <i>et al</i> "Erwinia soft rot resistance of potato cultivars transformed with a gene construct coding for antimicrobial peptide Cecropin B is not altered" <i>American Potato J.</i> , 1995, 72:437-445.	
	R2	BORDUSA, F. and H-D. JAKUBKE "the Specificity of Prolyl Endopeptidase from <i>Flavobacterium meningoseptum</i> : Mapping the S' Subsites by Positional Scanning via Acyl Transfer" <i>Bioorganic & Medicinal Chemistry</i> , 1998, 6:1775-1780.	
	R3	BOROVSKY, D. and F. MAHMOOD "Feeding the mosquito <i>Aedes aegypti</i> with TMOF and its analogs; effect on trypsin biosynthesis and egg development" <i>Regulatory Peptides</i> , 1995, 57:273-281.	
	R4	BOROVSKY, D. <i>et al</i> . "Development of Specific RIA and ELISA to Study Trypsin Modulating Oostatic Factor in Mosquitoes" <i>Archives of Insect Biochemistry and Physiology</i> , 1992, 21:13-21.	
	R5	BOROVSKY, D. <i>et al</i> . "Mosquito Oostatic Hormone" <i>Insect Neuropeptides: Chemistry, Biology Action</i> , 1991, 135-142.	
	R6	BYLEMANS, D. <i>et al</i> . "Immunolocalization of the Oostatic and Prothoracicostatic Peptide, Neb-TMOF, in Adults of the fleshfly, <i>Neobellieria bullata</i> " <i>General and Comparative Endocrinology</i> , 1996, 103:273-280.	
	R7	BYLEMANS, D. <i>et al</i> . "Neb-colloostatin, a second folliculostatin of the grey fleshfly, <i>Neobellieria bullata</i> " <i>Eur. J. Biochem.</i> , 1995, 228:45-49.	
	R8	BYLEMANS, D. <i>et al</i> . "Sequencing and characterization of trypsin modulating oostatic factor (TMOF) from the ovaries of the grey fleshfly, <i>Neobellieria (Sarcophaga) bullata</i> " <i>Reg. Peptides</i> , 1994, 50:61-72.	
	R9	BOSCH, D. <i>et al</i> . "A trout growth hormone is expressed, correctly folded and partially glycosylated in the leaves but not the seeds of transgenic plants" <i>Transgenic Res.</i> , 1994, 3:304-310.	
	R10	CHARBONNEAU, H. "Strategies for Obtaining Partial Amino Acid Sequence Data from Small Quantities (>5nmol) of Pure or Partially Purified Protein" <i>A Practical Guide to Protein and Peptide Purification for Microsequencing</i> , 1989, pp. 15-30.	
	R11	CHEE, M. <i>et al</i> . Accession Nos. P16753, Q69030.	
	R12	COPLEY <i>et al</i> . "Expression, processing and secretion of a proteolytically-sensitive insect diuretic hormone..." <i>Biochem.</i> , 1998, 330:1333-1340.	
	R13	DAHLEN, J.R. <i>et al</i> . "Expression, Purification and Inhibitory Properties of Human Proteinase Inhibitor" <i>Biochemistry</i> , 1997, 35:14874-14882.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/062,623
Filing Date	January 31, 2002
First Named Inventor	Dov Borovsky
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	UF-216C1

Sheet 5 of 8

TECH CENTER 1600/2900
APR 02 2002

+ RECEIVED

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	DE BOLLE, M. <i>et al.</i> "Antimicrobial peptides from <i>Mirabilis jalapa</i> and <i>Amaranthus caudatus</i> : expression, processing, localization and biological activity in transgenic tobacco" <i>Plant Mole. Biol.</i> , 1996, 31:993-1008.	
	R15	DESLAURIERS <i>et al.</i> "Steric Effects of Cis-Trans Isomerism on Neighboring Residues in Proline Oligopeptides: A C-NMR Study of conformational Heterogeneity in Linear Tripeptides" <i>Biopolymers</i> , 1979, 18(3):523-538.	
	R16	EIPPER <i>et al.</i> "The Biosynthesis of Neuropeptides: Peptide Amidation" <i>Annu. Rev. Neurosci.</i> , 1992, 15:57-85.	
	R17	GAUTHIER <i>et al.</i> "Direct Submission" <i>Plant Physiol.</i> , 1995, 108:1341. (abstract/sequence only).	
	R18	HENDERSON <i>et al.</i> "Physicochemical studies of biologically active peptides by low-temperature reversed-phase high-performance liquid chromatography" <i>Chemical Abstracts</i> , May 21, 1990, 112(21), abstract no. 192024, abstract only.	
	R19	HIGHTOWER, R. <i>et al.</i> "The expression of cecropin peptide in transgenic tobacco does not confer resistance to <i>Pseudomonas syringae</i> pv <i>tabaci</i> " <i>Plant Cell Reports</i> , 1994, 13:295-299.	
	R20	HLAVACEK <i>et al.</i> "The C-Terminus Shortened Analogs of the Insect Peptide Oostatic Hormone with Accelerated Activity" <i>Bioorg. Chem.</i> , October 1998, 26:131-140.	
	R21	HLAVACEK <i>et al.</i> "Synthesis, radiolabeling and biological activity of peptide oostatic hormone and its analogues" <i>J. Peptide Res.</i> , 1997, 50:153-158.	
	R22	HUA, Y-J. and J. KOOLMAN "An ecdysiotatin from flies" <i>Regulatory Peptides</i> , 1995, 57:263-271.	
	R23	JANSSEN, I. <i>et al.</i> "Biological Activity of Structural Analogs and Effect of Oil as a Carrier of Trypsin Modulating Oostatic Factor of the Gray Fleshfly <i>Neobellieria bullata</i> " <i>Peptides</i> , 1998, 19(4):627-634.	
	R24	KOLASKAR, A.S. and V. RAMABRAHMAM "Conformational properties of pairs of amino acids" <i>Int. J. Peptide Protein Res.</i> , 1983, 22:83-91.	
	R25	LADRAM <i>et al.</i> "Characterization of receptors for thyrotropin-releasing hormone-receptors potentiating peptide on rat anterior pituitary membranes" <i>J. Biol. Chem.</i> , 1992, 267(36):25697-25702.	
	R26	LIN, Y. <i>et al.</i> "Structure, Expression and Hormonal Control of Genes from the Mosquito, <i>Aedes aegypti</i> , Which Encode Proteins Similar to the Vitelline Membrane Proteins of <i>Drosophila melanogaster</i> " <i>Dev. Biology</i> , 1993, 155:558-568.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/062,623
Filing Date	January 31, 2002
First Named Inventor	Dov Borovsky
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	UF-216C1

Sheet 6 of 8

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R27	MASOUD, S.A. <i>et al.</i> "Expression of a cysteine proteinase inhibitor (oryzacystatin-I) in transgenic tobacco plants" <i>Plant Molecular Biology</i> , 1993, 21:655-663.	
	R28	MASUDA, N. <i>et al.</i> "Primary structure of protein moiety of <i>Penicillium notatum</i> phospholipase B deduced from the cDNA" <i>Eur. J. Biochem.</i> , 1991, 202:783-787.	
	R29	MEISSNER, H. <i>et al.</i> Accession No. O33838, November 1997.	
	R30	MENN <i>et al.</i> "Insect Neuropeptides: Potential New Insect Control Agents" <i>J. Agric. Food Chem.</i> , 1989, 37:271-274.	
	R31	MENZEL, D. <i>et al.</i> Accession No. P48579, 1995.	
	R32	MERKLER <i>et al.</i> "C-Terminal amidated peptides: Production by the <i>in vitro</i> enzymatic amidation of glycine-extended peptides and the importance of the amide to bioactivity" <i>Enzyme</i> , 1994, 16(6):450-456.	
	R33	NARBERHAUS <i>et al.</i> "The Bradyrhizobium japonicum rpoH1 gene encoding a sigma 32-like protein is part of a unique heat shock gene cluster together with groESL1 and three small heat shock genes" <i>J. Bacteriol.</i> , 1996, 178:5337-5346 (abstract/sequence only).	
	R34	NAUEN <i>et al.</i> "TMOF-like factor controls the biosynthesis of serine proteases in the larval gut of <i>Heliothis virescens</i> " <i>Arch. Insect. Biochem.</i> , 2001, 47:169-180.	
	R35	OKADA <i>et al.</i> "Synthesis of bradykinin fragments and their effect on pentobarbital sleeping time in mouse" <i>Chemical Abstracts</i> , November 7, 1977, 87(19), abstract no. 146142, abstract only.	
	R36	OKAMOTO, M. <i>et al.</i> "Enhanced Expression of an Antimicrobial Peptide Sarcotoxin IA by GUS Fusion in Transgenic Tobacco Plants" <i>Plant Cell Physiol.</i> , 1998, 39:57-63.	
	R37	PANG, S. <i>et al.</i> "Expression of a gene encoding a scorpion insectotoxin peptide in yeast, bacteria and plants" <i>Gene</i> , 1992, 116:165-172.	
	R38	PAULETTI <i>et al.</i> "Structural requirements for intestinal absorption of peptide drugs" <i>J. Controlled Rel.</i> , 1996, 41:3-17.	
	R39	RAYNE, R.C. and M. O'SHEA "Inactivation of Neuropeptide Hormones (AKH I and AKH II) Studied <i>In Vivo</i> and <i>In Vitro</i> " <i>Insect Biochem. Molec.</i> , 1992, 22(1):25-34.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

APR 02 2003

RECEIVED



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/062,623
Filing Date	January 31, 2002
First Named Inventor	Dov Borovsky
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	UF-216C1

Sheet 7 of 8

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R40	ROGINA, B. <i>et al.</i> Accession Nos. P24342, Q90780, 1992.	
	R41	ROURKE <i>et al.</i> "Heterologous Expression of Human Cholecystokinin in <i>Saccharomyces cerevisiae</i> " <i>J. Biol. Chem.</i> , 1997, 15:9720-9727.	
	R42	RUDINGER "Characteristics of the amino acids as components of a peptide hormone sequence" June 1976, pp. 1-7, In <i>Peptide Hormones</i> , Parsons (ed.), University Park press, Baltimore.	
	R43	SCHARTAU, W. <i>et al.</i> Accession No. X16893, 1990.	
	R45	SCHWARTZ, J.C. <i>et al.</i> "Biological Inactivation of Enkephalins and the Role of Enkephalin-Dipeptidyl-Carboxypeptidase ("Enkephalinase") as Neuropeptidase" <i>Life Sciences</i> , 1981, 29:1715-1740.	
	R46	SHIBNEV <i>et al.</i> "Synthesis of monomers that are triplets of the "crystalline" part of the collagen molecule" <i>Chemical Abstracts</i> , June 23, 1969, 70(25):392-397, abstract only.	
	R47	SOBER, H.A. "Handbook of Biochemistry" The Chemical Rubber Co., Cleveland, Ohio, 1968, page C70.	
	R48	SOUTHWICK, F.S. and D.L. PURICH "Inhibition of <i>Listeria</i> Locomotion by Mosquito Oostatic Factor, a Natural Oligoproline Peptide Uncoupler of Profilin Action" <i>Infection and Immunity</i> , 1995, 63(1):182-190.	
	R49	STONE, S. <i>et al.</i> Accession No. P11493, 1997.	
	R50	TAYLOR, M. "Trypsin Isolated from the Midgut of the Tobacco Hornworm, <i>Manduca Sexta</i> , Inhibited by Synthetic Pro-peptides <i>in Vitro</i> " <i>Biochem. and Biophys. Res. Comm.</i> , 1997, 235:606-609.	
	R51	TYKVA, R. <i>et al.</i> "The fate of an oostatic peptide or its analogs including metabolites in insects Diptera and Orthoptera and its transformation to the next generation" <i>Chemical Abstracts</i> , 132(26), abstract no. 345576.	
	R52	VAECK, M. <i>et al.</i> "Transgenic plants protected from insect attack" <i>Nature</i> , 1987, 328:33-37.	
	R53	VOIT, R. and G. FELDMAIER-FUCHS "Arthropod Hemocyanins. Molecular Cloning and Sequencing of cDNAs Encoding the Tarantula Hemocyanin Subunits a and e" <i>J. Biol. Chem.</i> , November 15, 1990, 265:19447-19452.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/062,623
Filing Dat	January 31, 2002
First Named Inventor	Dov Borovsky
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	UF-216C1

Sheet 8 of 8

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	R54	YOUN, H. <i>et al.</i> Accession No. Q9JP84, 1998.
	R55	
	R56	
	R57	
	R58	
	R59	
	R60	
	R61	
	R62	
	R63	
	R64	
	R65	
	R66	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+ RECEIVED

APR 17 2003
TECH CENTER 1600 2900